Meet Our Team
Bios Partners has a combined 90+ years of experience in hedge funds, private equity, clinical drug development and public pharma/biotech analysis to fill the CEO’s experiential void.
Dr. Fletcher is managing director of Bios Partners, a life sciences venture firm based in Fort Worth, Texas and founded and serves as president of Bios Research, a financial services firm that provides public equity research in the healthcare space tailored to institutional firms. Bios Research provides fundamental healthcare industry research focused in the biotech and med-tech sub-sectors and through this research, Dr. Fletcher has a strong understanding of commercial viability in the marketplace. Dr. Fletcher holds a Ph.D. in biochemistry from Colorado State University and currently serves as a visiting professor at Dallas Baptist University. Dr. Fletcher has worked as an independent consultant for the biotech/healthcare equity industry for more than 10 years and has extensive experience at companies covering a variety of diagnostic and therapeutic areas including oncology.
Kreis has over 25 years of investment experience across many types of financial instruments in both global public and private equity markets. Currently, he is the Managing Principal at Steelhead Capital Management, which manages a portfolio of small business investments and start-up ventures. Mr. Kreis is also a founding member of Cowtown Angels, a Fort Worth-based angel investment network. Prior to this, Mr. Kreis was a Vice President at HBK Investments, a multi-strategy global hedge fund based in Dallas, TX. During his 11-year tenure with the firm, he managed a $3 billion global portfolio composed of stocks, bonds and derivatives products. He was one of two professionals responsible for launching HBK’s London office, and he traded in many financial markets including Japan, India, Europe, United Kingdom, Canada and the U.S. Mr. Kreis received a BBA in Finance from Texas Christian University in 1994.
Dr. Robertson has over 25 years of experience in pharmaceutical Research and Development, including R&D strategies, project management, clinical trials, regulatory filings, product launch, market support, translational medicine, and medical communication. Dr. Robertson is a co-founder of Bios Partners, LP, a member of Cowtown Angels and the owner of Arrochar Consulting LLC. She formerly was a Vice President in Research and Development at Alcon Laboratories, Inc., where she grew and led organizations that were responsible for the ophthalmic pipeline, designing and developing ophthalmic and otic pharmaceuticals and medical devices, achieving over fifteen global product approvals. She received a PhD in biology-immunology from Johns Hopkins University, was an Arthritis Foundation postdoctoral research fellow at UTHSC Dallas, and completed the Program for Management Development at Harvard Business School. She holds a number of patents and is a co-author of over fifty publications. She serves on the boards of early-stage companies and volunteers with the incubator-accelerator TechFW, local university entrepreneurial programs, and ARVO’s Women in Eye and Vision Research.
John Fucci is a Partner at Bios Partners, a biotech venture capital firm based in Fort Worth, TX. Mr. Fucci focuses on diligence and negotiations of new investment opportunities, portfolio company management, and investor relations. Currently, he serves on the board of Lantern Pharma, a New Jersey based clinical-staged precision oncology company. Previously, he was a Vice President at Steelhead Capital Management (SCM), a Fort Worth, TX based family office investing in biotechnology, crypto currency, real estate, energy, consumer packaged goods and early staged venture capital investing. Mr. Fucci double majored in Finance and Entrepreneurial Management at Texas Christian University.
Ms. de la Garza has over five years’ experience in financial and scientific analysis as an analyst at Bios Research and Bios Partners. Ms. de la Garza has developed a strong understanding of healthcare market dynamics and commercial viability therein. She received her Bachelor of Science degree (BS) in Biology from Dallas Baptist University and her Masters of Public Health (MPH) from the UT Health Science Center at Houston with a concentration in epidemiology and global health. She is currently working on her Ph.D. at Dallas Baptist University in Leadership Studies.
Mr. Schwarz has over 17 years of experience in investment management and financial services industries across accounting, operations, and investor relations. Currently, he is CFO/COO of Bios Partners, a biotech venture capital firm based in Fort Worth, Texas. Prior to this, Mr. Schwarz was an Associate Director at Crestline, a $9 billion credit-focused institutional asset manager. Previously, Mr. Schwarz was a Senior Auditor with KPMG, LLP specializing in investment managers. Mr. Schwarz is a graduate of Texas A&M University where he received his B.B.A. in Accounting and M.S. in Finance. In addition, he has been a Certified Public Accountant in the State of Texas since 2004.
Stephen Phillips is the Vice President at Bios Partners. Mr. Phillips focuses on diligence and negotiations of new investment opportunities, portfolio company management, and investor relations. Previously, he was Vice President at Moorea Capital, LLC, a Plano, TX-based family office investing in biotechnology, real estate, and operating companies. Mr. Phillips majored in Management and received his M.B.A. from Dallas Baptist University. While attending DBU, he served as chapter president of the national leadership society, Omicron Delta Kappa.
Dr. Van Treuren joined Bios Partners in January of 2019. Dr. Van Treuren has over eight years of hands-on laboratory experience which led to a robust knowledge of a wide range of cellular processes and how they relate to both the cell and the body as a whole. His time in the lab has also provided him with a comprehensive and analytical understanding of the research process, especially within oncology. He earned his Ph.D. in Biomedical Sciences with an emphasis in Cancer Biology from the University of North Texas Health Science Center in Fort Worth, TX.
Blake Pate is Vice President of Investments at Bios Partners where he joined in May 2019. At Bios, Blake focuses on investment due diligence, deal flow, and frequently attends banking conferences and medical meetings. Blake also serves as Vice President of Bios Research, a financial services firm that provides public equity research in the healthcare space tailored to institutional firms. Prior to joining Bios Partners, Blake received his BS in Biology and a business minor in May 2019. He also trained in biostatistics, data analysis, and algorithm development while assisting the HPV Working Group at the Yale University School of Medicine. Most recently, Blake received his Master of Science in Biotechnology with a concentration in Enterprise and Entrepreneurship at Johns Hopkins University. Blake also serves as an advisory board member to the DBU College of Business and is a Network Partner for 2048 Ventures.
Mr. Osborn is a Controller at Bios Partners. Prior to starting with Bios Partners in June of 2019, Mr. Osborn worked as an auditor at KPMG LLP, specializing in private equity and hedge fund accounting. Mr. Osborn received his Master’s degree in Accounting from Abilene Christian University.